Class I PI3K in oncogenic cellular transformation.
Class I phosphoinositide 3-kinase (PI3K) is a dimeric enzyme, consisting of a catalytic and a regulatory subunit. The catalytic subunit occurs in four isoforms designated as p110 alpha, p110 beta, p110 gamma and p110 delta. These isoforms combine with several regulatory subunits; for p110 alpha, beta and delta, the standard regulatory subunit is p85, for p110 gamma, it is p101. PI3Ks play important roles in human cancer. PIK3CA, the gene encoding p110 alpha, is mutated frequently in common cancers, including carcinoma of the breast, prostate, colon and endometrium. Eighty percent of these mutations are represented by one of the three amino-acid substitutions in the helical or kinase domains of the enzyme. The mutant p110 alpha shows a gain of function in enzymatic and signaling activity and is oncogenic in cell culture and in animal model systems. Structural and genetic data suggest that the mutations affect regulatory inter- and intramolecular interactions and support the conclusion that there are at least two molecular mechanisms for the gain of function in p110 alpha. One of these mechanisms operates largely independently of binding to p85, the other abolishes the requirement for an interaction with Ras. The non-alpha isoforms of p110 do not show cancer-specific mutations. However, they are often differentially expressed in cancer and, in contrast to p110 alpha, wild-type non-alpha isoforms of p110 are oncogenic when overexpressed in cell culture. The isoforms of p110 have become promising drug targets. Isoform-selective inhibitors have been identified. Inhibitors that target exclusively the cancer-specific mutants of p110 alpha constitute an important goal and challenge for current drug development.
Zhao
L
L
Division of Oncovirology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. leyna@scripps.edu
Vogt
P K
PK
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000032:analysis / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000502:physiology; D008954:Models, Biological; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000145:classification / Q000235:genetics / Q000502:physiology; D021122:Protein Subunits / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D009687:Nuclear Proteins; C503859:PI3KCA protein, human; D021122:Protein Subunits; D014157:Transcription Factors; D019869:Phosphatidylinositol 3-Kinases
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1289-94
16432180
Mol Cell Biol. 1994 Apr;14(4):2675-85
8139567
J Biol Chem. 1998 May 29;273(22):13375-8
9593664
Immunity. 2002 Mar;16(3):441-51
11911828
J Biol Chem. 2003 Oct 3;278(40):38437-42
12869549
Science. 2000 Feb 11;287(5455):1046-9
10669417
Cancer Res. 2005 Jun 1;65(11):4562-7
15930273
Cell. 1998 Oct 2;95(1):29-39
9778245
J Biol Chem. 1999 Apr 16;274(16):10963-8
10196176
Biochim Biophys Acta. 1998 Aug 21;1376(2):155-72
9748550
Oncogene. 2004 Apr 19;23(18):3145-50
15094764
Biochem Soc Trans. 2004 Apr;32(Pt 2):315-9
15046598
Carcinogenesis. 2007 Jul;28(7):1379-86
17341655
Mol Cell. 2004 May 21;14(4):416-8
15149589
Trends Cell Biol. 1998 Nov;8(11):442-6
9854311
Cell. 2000 Dec 8;103(6):931-43
11136978
Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62
17052169
J Cell Sci. 2000 Jan;113 Pt 2:207-14
10633072
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6
10377430
Hum Mutat. 2005 Mar;25(3):322
15712344
Oncogene. 2008 Apr 17;27(18):2561-74
17998941
Cancer Res. 2004 Nov 1;64(21):7678-81
15520168
Cancer Res. 2005 Dec 1;65(23):10992-1000
16322248
Biochem J. 2004 Aug 15;382(Pt 1):1-11
15193142
Cancer Biol Ther. 2004 Aug;3(8):772-5
15254419
Nat Rev Cancer. 2002 Jul;2(7):489-501
12094235
Nature. 2008 May 29;453(7195):662-6
18449193
Nature. 1999 Apr 15;398(6728):630-4
10217147
Cancer Res. 2004 Aug 1;64(15):5048-50
15289301
Oncogene. 2005 Feb 17;24(8):1477-80
15608678
Cell. 1999 Mar 19;96(6):857-68
10102273
Cancer Res. 2003 Apr 1;63(7):1667-75
12670921
Biochem J. 2008 Jan 15;409(2):519-24
17877460
Mol Cell Biol. 2004 Feb;24(3):966-75
14729945
Science. 2007 Dec 14;318(5857):1744-8
18079394
Science. 2006 Dec 1;314(5804):1458-61
17095657
Biochem Soc Trans. 2007 Apr;35(Pt 2):242-4
17371249
J Cell Biol. 2003 Aug 18;162(4):613-22
12913110
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8
9811831
Science. 2002 May 31;296(5573):1655-7
12040186
Blood. 2005 Aug 1;106(3):1063-6
15840695
Clin Cancer Res. 2005 Apr 15;11(8):2875-8
15837735
Trends Cell Biol. 2002 Dec;12(12):579-85
12495846
Exp Cell Res. 1999 Nov 25;253(1):239-54
10579926
Trends Biochem Sci. 2005 Apr;30(4):194-204
15817396
Curr Biol. 2003 Aug 5;13(15):1259-68
12906785
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7
15647370
Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9
12927784
Cell. 2006 May 19;125(4):733-47
16647110
Brain Pathol. 2004 Oct;14(4):372-7
15605984
Nature. 2000 Apr 13;404(6779):782-7
10783894
J Exp Med. 2002 Sep 16;196(6):753-63
12235209
Exp Cell Res. 2001 Mar 10;264(1):29-41
11237521
Biochem Soc Trans. 2004 Apr;32(Pt 2):330-1
15046601
Cell Motil Cytoskeleton. 2004 Nov;59(3):180-8
15468162
Mol Cell Biol. 2002 Dec;22(24):8580-91
12446777
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5569-74
17376864
Cell Cycle. 2008 May 1;7(9):1151-6
18418043
J Cell Biol. 2004 Jul 19;166(2):213-23
15249583
EMBO J. 1996 May 15;15(10):2442-51
8665852
Oncogene. 1993 Apr;8(4):841-7
8384355
Cell. 1991 Apr 5;65(1):83-90
1849461
Nature. 1999 Nov 18;402(6759):313-20
10580505
Science. 2004 Apr 23;304(5670):554
15016963
J Immunol. 2008 Feb 15;180(4):2538-44
18250464
Mamm Genome. 2002 Mar;13(3):169-72
11919689
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11836-41
10518537
Nat Rev Cancer. 2006 Mar;6(3):184-92
16453012
Cell. 2008 May 2;133(3):403-14
18455982
Trends Biochem Sci. 2007 Jul;32(7):342-9
17561399
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2652-7
18268322
Nat Rev Cancer. 2005 Dec;5(12):921-9
16341083
J Cell Biol. 2005 Aug 1;170(3):455-64
16043515
Cancer Cell. 2002 Mar;1(2):181-91
12086876
Cell Cycle. 2005 Apr;4(4):578-81
15876869
Cell. 1994 Apr 8;77(1):83-93
8156600
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1475-9
16432179
Oncogene. 1993 Apr;8(4):833-40
8384354
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8
16339315
J Biol Chem. 2005 Jul 29;280(30):27850-5
15932879
J Biol Chem. 1998 Jun 26;273(26):15879-82
9632630
FEBS J. 2008 Jan;275(2):371-85
18081863
Annu Rev Biochem. 2001;70:535-602
11395417
Nature. 1994 Aug 18;370(6490):527-32
8052307
J Biol Chem. 1999 Jun 11;274(24):16741-6
10358014
Mol Cell Biol. 1998 Mar;18(3):1379-87
9488453
Science. 2000 Feb 11;287(5455):1040-6
10669416
Nat Cell Biol. 2006 Nov;8(11):1303-9
17041586
Nat Rev Immunol. 2003 Apr;3(4):317-30
12669022
Biochem Soc Trans. 2007 Apr;35(Pt 2):245-9
17371250
Nat Cell Biol. 2002 Sep;4(9):648-57
12172553
Curr Biol. 1997 Apr 1;7(4):261-9
9094314
Nature. 2004 Oct 21;431(7011):1007-11
15496927
Mol Cell. 2003 Jun;11(6):1457-66
12820960
Cell. 2004 Apr 16;117(2):211-23
15084259
Nat Cell Biol. 1999 May;1(1):69-71
10559867
Cancer Cell. 2005 Jul;8(1):25-33
16023596
Genes Dev. 2003 Aug 1;17(15):1829-34
12869586
EMBO J. 1994 Feb 1;13(3):522-33
8313897
Annu Rev Cell Dev Biol. 2001;17:615-75
11687500
Curr Opin Oncol. 2006 Jan;18(1):77-82
16357568
Trends Biochem Sci. 1997 Jul;22(7):267-72
9255069
J Biol Chem. 2003 Dec 19;278(51):51606-12
14563837
Neuropathol Appl Neurobiol. 2005 Oct;31(5):486-90
16150119
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4330-5
9113989
Science. 2002 Aug 9;297(5583):1031-4
12130661
J Cell Biol. 2001 Feb 19;152(4):717-28
11266463
J Biol Chem. 2006 Feb 3;281(5):2441-50
16291747
Annu Rev Biochem. 2001;70:247-79
11395408
EMBO J. 1997 Oct 15;16(20):6151-61
9321394
Science. 2007 Jul 13;317(5835):239-42
17626883
Protein Sci. 1996 Dec;5(12):2375-90
8976547
Cancer Res. 2005 Apr 1;65(7):2554-9
15805248
J Immunol. 2002 May 15;168(10):5024-31
11994454
Science. 2000 Feb 11;287(5455):1049-53
10669418
J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32
10564676
Oncogene. 2000 Oct 19;19(44):5083-90
11042696
Science. 2005 Feb 18;307(5712):1098-101
15718470
Nat Cell Biol. 2003 Jun;5(6):578-81
12771962
J Immunol. 2003 May 1;170(9):4475-82
12707323
Blood. 2007 Oct 15;110(8):2940-7
17626838
Nature. 2006 May 18;441(7091):366-70
16625210
BMC Cancer. 2005 Mar 23;5:29
15784156
Nature. 1995 Dec 21-28;378(6559):785-9
8524413
Hum Mutat. 2003 Sep;22(3):183-98
12938083
Genes Dev. 2000 Oct 1;14(19):2501-14
11018017
Cancer Res. 2007 Jun 15;67(12):5840-50
17575152
Nat Rev Genet. 2006 Aug;7(8):606-19
16847462
Annu Rev Immunol. 2004;22:563-98
15032589
Acta Neuropathol. 2005 Jun;109(6):639-42
15924253
Cell Cycle. 2006 Apr;5(7):675-7
16627990